E N D
1. TRITON-TIMI 38 and PRINCIPLE-TIMI 44 Trials of Prasugrel Stephen D. Wiviott, MD
Brigham and Women’s Hospital
Boston, MA, USA
7. TRITON TIMI 38 Main Trial Design
9. TRITON TIMI 38 CV death, MI, stroke:Major subgroups
10. TRITON TIMI 38 Total Events Prevented: First and Recurrent
12. TRITON TIMI 38 Net clinical benefit: Bleeding risk subgroups
13. Definite/probable ST: Any stent (n = 12,844)
14. Stent thrombosis subgroups